A new JACC Focus Issue on Valve Disease “brings together pivotal trials, state-of-the-art reviews and expert guidance that reflect the field's rapid evolution, from earlier intervention to more refined device selection and longitudinal care,” writes JACC Editor-in-Chief Harlan M. Krumholz, MD, SM, FACC. Read insights from the EARLY-TAVR trial, one-year outcomes from the LANDMARK trial in severe aortic stenosis, a comprehensive state-of-the-art review on aortic regurgitation, the 2025 ACC Expert Consensus Decision Pathway on tricuspid regurgitation and more. Read the full issue.